ArticleJapanese journal of clinical oncology2023

The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance.

Hirotsugu Uemura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.